-
1
CLINICAL AND ECONOMICAL ASPECTS OF NOVEL APPROACHES TO THE TREATMENT OF CHRONIC HEART FAILURE DECOMPENSATION
Published 2015-03-01Subjects: Get full text
Article -
2
-
3
A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP)
Published 2020-03-01Subjects: Get full text
Article -
4
NEW PROSPECTS IN PHARMACOLOGICAL TREATMENT OF ACUTE DECOMPENSATED HEART FAILURE. EXPERIENCE WITH SERELAXIN. A CLINICAL CASE
Published 2017-12-01Subjects: Get full text
Article -
5
Involvement of cyclic guanosine monophosphate-dependent protein kinase I in renal antifibrotic effects of serelaxin
Published 2016-07-01Subjects: Get full text
Article -
6
-
7
Organoprotective effects of serelaxin in patients with severe decompensated heart failure
Published 2016-09-01Subjects: Get full text
Article -
8
Serelaxin Protects H9c2 Cardiac Myoblasts against Hypoxia and Reoxygenation-Induced Damage through Activation of AMP Kinase/Sirtuin1: Further Insight into the Molecular Mechanisms...
Published 2024-01-01Subjects: “…Serelaxin…”
Get full text
Article -
9
Serelaxin Improves Regional Myocardial Function in Experimental Heart Failure: An In Vivo Cardiac Magnetic Resonance Study
Published 2020-02-01Subjects: Get full text
Article -
10
Proportional pulse pressure relates to cardiac index in stabilized acute heart failure patients
Published 2018-10-01Subjects: Get full text
Article -
11
-
12
RXFP1 Receptor Activation by Relaxin-2 Induces Vascular Relaxation in Mice via a Gαi2-Protein/PI3Kß/γ/Nitric Oxide-Coupled Pathway
Published 2018-09-01Subjects: “…serelaxin…”
Get full text
Article